复旦张江(01349) - 2022 Q3 - 季度财报

Financial Summary and Performance Highlights The company reported significant Q3 2022 revenue and net profit growth, though year-to-date net profit declined sharply due to increased share-based payment expenses Key Financial Data In Q3 2022, the company achieved significant year-on-year growth in operating revenue and net profit, while year-to-date net profit saw a substantial decline, influenced by increased share-based payment expenses | Item | Current Period (Q3 2022) (RMB Yuan) | YoY Change (%) in Current Period | Year-to-Date (First Three Quarters) (RMB Yuan) | YoY Change (%) Year-to-Date | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 445,006,305 | 48.79% | 716,265,980 | 2.60% | | Net Profit Attributable to Shareholders of the Listed Company | 72,798,391 | 37.02% | 36,823,845 | -68.95% | | Net Profit Attributable to Shareholders of the Listed Company (Excluding Non-Recurring Gains/Losses) | 67,906,975 | 43.50% | 22,288,451 | -78.12% | | Basic Earnings Per Share (RMB/share) | 0.07 | 40.00% | 0.04 | -63.64% | | Total R&D Investment | 71,029,256 | 0.37% | 177,874,093 | -0.22% | | R&D Investment as % of Operating Revenue (%) | 15.96% | Decreased by 7.70 percentage points | 24.83% | Decreased by 0.71 percentage points | | Item | End of Current Period (RMB Yuan) | End of Previous Year (RMB Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 2,908,473,496 | 2,781,172,268 | 4.58% | | Total Equity Attributable to Shareholders of the Listed Company | 2,216,277,478 | 2,192,945,932 | 1.06% | Non-Recurring Gains and Losses In the first three quarters of 2022, the company recorded total non-recurring gains of approximately RMB 14.54 million, primarily from structured deposit interest and government grants | Item | Amount Year-to-Date (RMB Yuan) | Description | | :--- | :--- | :--- | | Fair Value Changes and Investment Income from Financial Assets | 14,026,034 | Primarily interest from the Group's structured deposits | | Government Grants Recognized in Current Profit/Loss | 2,481,052 | / | | Gains/Losses on Disposal of Non-Current Assets | 1,381,059 | / | | Other Non-Operating Income and Expenses | -787,646 | / | | Total | 14,535,394 | / | Analysis of Changes in Key Financial Indicators Q3 revenue and profit growth were driven by post-epidemic recovery, while year-to-date net profit decline was primarily due to increased share-based payment expenses, and operating cash flow improved from extended payment cycles - Operating revenue and related profit indicators in the current reporting period (Q3) significantly increased year-on-year, primarily due to the recovery of drug production and sales after the Shanghai epidemic was brought under control[5] - Year-to-date, net profit attributable to parent company decreased by 68.95% year-on-year, and non-recurring net profit attributable to parent company decreased by 78.12%, mainly due to share-based payment expenses of RMB 68.4417 million, compared to RMB 23.7992 million in the same period last year[5] - Year-to-date, net cash flow from operating activities increased by 33.40% year-on-year, primarily due to extended payment cycles for accounts payable[5] Shareholder Information As of the reporting period end, the company had 21,351 common shareholders, with the top five shareholders holding over 70% of shares Shareholder Profile and Top Ten Shareholders As of the reporting period end, the company had 21,351 common shareholders, with a concentrated equity structure where the top five shareholders collectively held over 70% of shares - As of the end of the current reporting period, the company had a total of 21,351 common shareholders, including 21,211 A-share holders and 140 H-share holders[6] | Shareholder Name | Shareholding (%) | Number of Shares Held | | :--- | :--- | :--- | | HKSCC NOMINEES LIMITED | 21.79 | 224,234,900 | | Shanghai Pharmaceuticals Holding Co., Ltd. | 20.42 | 210,142,560 | | Xinqi Phase II Venture Capital Enterprise | 15.25 | 156,892,912 | | Yang Zongmeng | 7.77 | 80,000,000 | | Wang Haibo | 5.63 | 57,886,430 | Consolidated Financial Statements The company's total assets increased by 4.58% to RMB 2.91 billion, while total liabilities rose by 17.59% to RMB 695.64 million, and net profit attributable to parent company declined by 68.95% year-to-date Consolidated Balance Sheet As of September 30, 2022, total assets reached RMB 2.91 billion, increasing by 4.58% driven by construction in progress, while total liabilities grew by 17.59% due to higher other payables | Item | September 30, 2022 (RMB Yuan) | December 31, 2021 (RMB Yuan) | Change | | :--- | :--- | :--- | :--- | | Total Assets | 2,908,473,496 | 2,781,172,268 | +4.58% | | Cash and Cash Equivalents | 1,237,143,906 | 1,208,880,911 | +2.34% | | Construction in Progress | 112,124,690 | 48,899,044 | +129.29% | | Total Liabilities | 695,635,874 | 591,582,298 | +17.59% | | Other Payables | 577,314,935 | 443,978,184 | +30.03% | | Total Equity Attributable to Parent Company Owners | 2,216,277,478 | 2,192,945,932 | +1.06% | Consolidated Income Statement In the first three quarters of 2022, total operating revenue slightly increased by 2.6%, but rising operating costs led to a 73.46% decline in operating profit and a 68.95% drop in net profit attributable to parent company | Item | First Three Quarters of 2022 (RMB Yuan) | First Three Quarters of 2021 (RMB Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 716,265,980 | 698,113,963 | +2.60% | | Total Operating Costs | 667,789,596 | 592,930,829 | +12.62% | | Of which: Selling Expenses | 383,823,070 | 346,570,728 | +10.75% | | Administrative Expenses | 55,061,168 | 38,043,903 | +44.73% | | R&D Expenses | 171,893,365 | 159,207,486 | +8.00% | | Operating Profit | 30,756,721 | 115,898,651 | -73.46% | | Net Profit Attributable to Parent Company Shareholders | 36,823,845 | 118,614,270 | -68.95% | | Basic and Diluted Earnings Per Share (RMB/share) | 0.04 | 0.11 | -63.64% | Consolidated Cash Flow Statement In the first three quarters of 2022, net cash flow from operating activities increased by 33.40% to RMB 196.18 million, while net cash outflow from investing activities significantly narrowed | Item | First Three Quarters of 2022 (RMB Yuan) | First Three Quarters of 2021 (RMB Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 196,182,795 | 147,058,878 | +33.40% | | Net Cash Flow from Investing Activities | -79,977,072 | -535,542,863 | Not Applicable | | Net Cash Flow from Financing Activities | -88,302,716 | -88,889,372 | Not Applicable | | Net Increase in Cash and Cash Equivalents | 28,262,995 | -477,392,996 | Not Applicable | | Cash and Cash Equivalents at Period End | 1,237,143,906 | 919,497,196 | +34.55% | Other Important Information The company reported no other significant operational information requiring investor attention, and the quarterly report was approved by the Board of Directors on October 27, 2022 Other Important Reminders The company has no other significant information regarding its operations that requires investor attention during the current reporting period - The company has no other significant information regarding its operations that requires investor attention during the current reporting period[7] Board of Directors Information The quarterly report was approved by the Board of Directors on October 27, 2022, with a detailed list of executive, non-executive, and independent non-executive directors - These financial statements were approved for issuance by the Company's Board of Directors on October 27, 2022[13] - Board members include Executive Directors Wang Haibo, Su Yong, Zhao Dajun; Non-Executive Directors Shen Bo, Yu Xiaoyang; and Independent Non-Executive Directors Zhou Zhonghui, Lin Yaojian, Xu Qing, Yang Chunbao[14]